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Background: The PORTEC-2 trial showed efficacy and reduced side-effects of vaginal brach-
ytherapy (VBT) compared with external beam pelvic radiotherapy (EBRT) for patients with
high-intermediate risk endometrial cancer. The current analysis was done to evaluate
long-term health related quality of life (HRQL), and compare HRQL of patients to an age-
matched norm population.
Methods: Patients were randomly allocated to EBRT (n = 214) or VBT (n = 213). HRQL was
assessed using EORTC QLQ-C30 and subscales from PR25 and OV28 (bladder, bowel, sexual
symptoms); and compared to norm data.
Findings: Median follow-up was 65 months; 348 (81%) patients were evaluable for HRQL
(EBRT n = 166, VBT n = 182). At baseline, patient functioning was at lowest level, increasing
during and after radiotherapy to reach a plateau after 12 months, within range of scores of
the norm population. VBT patients reported better social functioning (p = 0.005) and lower
symptom scores for diarrhoea, faecal leakage, need to stay close to a toilet and limitation in
daily activities due to bowel symptoms (p 6 0.001), compared to EBRT. There were noo. ISRCTN16228756.
t of Clinical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The
(0)71 5266760.
ut).
he Elsevier OA license. 
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Toxicitydifferences in sexual functioning or symptoms between the treatment groups; however,
sexual functioning was lower and sexual symptoms more frequent in both treatment
groups compared to the norm population.
Interpretation: Patients who received EBRT reported clinically relevant higher levels of bowel
symptoms and related limitations in daily activities with lower social functioning, 5 years
after treatment. VBT provides a better HRQL, which remained similar to that of an age-
matched norm population, except for sexual symptoms which were more frequent in both
treatment groups.
 2011 Elsevier Ltd.Open access under the Elsevier OA license. 1. Introduction
Endometrial carcinoma (EC) is the most common gynaecolog-
ical malignancy among postmenopausal women in Western
countries.1 Surgery, consisting of total abdominal (or laparo-
scopic) hysterectomy and bilateral salpingo-oophorectomy
(TAH-BSO) is the cornerstone of treatment.
Randomised trials have shown that pelvic external beam
radiotherapy (EBRT) significantly reduced locoregional relapse,
but without survival benefit, and at the cost of more (predom-
inantly mild) gastro-intestinal toxicity.2–6 Risk factors for loco-
regional recurrence were tumour grade 3, outer 50%
myometrial invasion, age over 60 years and lymph-vascular
space invasion. Patients with these high-intermediate risk fea-
tures had the largest benefit from EBRT (20% locoregional re-
lapse without radiotherapy versus 5% with EBRT). As most
(75%) locoregional relapses were located in the vagina, the ran-
domised PORTEC-2 trial was initiated to investigate if vaginal
brachytherapy (VBT) would be equally effective for vaginal con-
trol, whilst reducing treatment toxicity and improving health
related quality of life (HRQL) as compared to EBRT. Final results
showed that VBTwas indeed very effective in preventing vagi-
nal recurrence with an estimated vaginal recurrence rate of 2%
at 5 years, similar to the results obtained with EBRT.7 Short-
term HRQL results up to 2 years after treatment showed that
rates of bowel symptoms such as diarrhoea and faecal leakage
were significantly lower among women treated with VBT, with
better social functioning compared to women treated with
EBRT.8 Symptom levels among VBT patients were very low.
These results prompted adoption of VBT as standard of care
for patients with high-intermediate risk EC in the Netherlands.
Analysis of HRQL among PORTEC-1 patients 15 years after
treatment showed that EBRT is associated with long-lasting
symptoms impacting on patient functioning.9 This finding
underscores the importance of longitudinal HRQL analysis
and reporting of late outcomes.
The current analysiswas done to evaluate 5-year HRQL after
EBRT and VBT of PORTEC-2 trial patients and compare their
HRQL with that of an age-matched Dutch norm population.
2. Patients and methods
2.1. Patient selection, treatment and study design of the
PORTEC-2 trial
The multicentre PORTEC-2 trial randomly allocated EC patients
with high-intermediate risk features to EBRTor VBT. Details onpatientselection,treatmentandHRQLhavebeendescribedinpre-
viouspublications.7,8Inshort,surgeryconsistedofTAH-BSO;clin-
ically suspicious pelvic and/or periaortic lymph nodes were
removed,butnoroutinelymphadenectomywasperformed.FIGO
1988stagingwasassignedonthebasisofsurgicalandpathological
findings.10 Patientswere eligible if they had one of the following
combinationsofage,gradeandFIGOstage:(1)ageP60yearsand
stage1Cgrade1or2orstage1Bgrade3;(2)stage2A,anyage(except
grade 3 with outer 50% myometrial invasion). Written informed
consent was obtained from all patients. The protocol was ap-
proved by the Dutch Cancer Society and the Ethics Committees
ofparticipatingcentres.
EBRT was given to a total dose of 46 Gy in 2 Gy daily frac-
tions, 5 fractions/week. VBT was delivered to the upper half
of the vagina using a vaginal cylinder. Brachytherapy dose
schedules were used, equivalent to 45–50 Gy to the vaginal
mucosa: high-dose-rate (90% of patients) 21 Gy at 5 mm depth
in 3 fractions of 7 Gy over 2 weeks; low-dose-rate (10%) 30 Gy
at 5 mm depth, in one session at 50–70 cGy/h.
The primary end-point was 5-year vaginal relapse (VR) as
cumulative incidence, accounting for death as competing
risk.11 Secondary end-points were HRQL, treatment related
toxicity, pelvic lymph node and distant relapse and overall
survival.
2.2. Quality-of-life assessment
Cancer-specific HRQL was measured with the EORTC (Euro-
pean Organization for Research and Treatment of Cancer)
Core questionnaire (QLQ-C30 version 3.0).12 No endometrial
cancer-specific symptom questionnaire was available at the
time; with approval of the EORTC Quality of Life Group, rele-
vant subscales from existing published EORTC modules were
combined into a symptom module (subscales for bowel and
bladder symptoms from PR25 and subscale for sexual func-
tioning and symptoms from OV28).13,14 For all items Likert-
type response scales were used, with response scales ranging
from 1 to 4 points for all items except for items 29 and 30 (re-
sponse scale 1–7). All subscales and individual item responses
were linearly converted to 0–100 scales. A higher score for a
functional and global quality of life scale represents a better
level of functioning. For the symptom scales and items, a
higher score reflects a higher level of symptoms and de-
creased HRQL.
Baseline HRQL questionnaires were handed out at first
consultation with the radiation oncologist 3–4 weeks after
surgery and were returned prior to RT. The end-of-treatment
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consent, subsequent questionnaires were sent directly to the
patient home address at 6, 12, 18, 24, 36, 48 and 60 months
from randomisation.
Patients were considered evaluable for the HRQL assess-
ment if they had returned the baseline questionnaire and at
least one of the follow-up questionnaires (‘responders’).
2.3. Statistical methods
All statistical analyses were performed using SPSS, version
17.0 (SPSS, Inc., Chicago, IL). Chi-square statistics or Fisher’s
exact test for categorical variables and t test for continuous
variables were used to compare patient and tumour charac-
teristics (significance p-value < 0.05).
HRQL analysis was done according to the guidelines pro-
vided by the EORTC Quality of life Group.15 Descriptive med-
ian scores are presented in the tables. Baseline scores of
both treatment groups were compared with a t test, or Armit-
age trend test for single items. In order to exclude a treatment
effect on baseline scores, baseline forms completed later than
the first day of radiotherapy were excluded for this compari-
son. To obtain estimates of the EORTC QLQ-C30, PR25 and
OV28 subscales at each of the fixed time points, a linear
mixed model was used with patient as random effect and
time (categorical), randomisation and their interaction as
fixed effects. Single items were analysed using (ordinal) logis-
tic regression with random effects. The difference in HRQL
between the two treatment groups was tested by Wald’s test
in the linear or ordinal logistic mixed model (p-randomisa-
tion), excluding the baseline value. The same test was applied
to look for significant changes of QOL scores over time (p-
time) and score changes over time were compared between
both treatment groups (p-time by randomisation), including
the baseline value. Age-matched Dutch norm population
means16 were compared with both treatment groups at each
time point using the t test. To guard against false positive re-
sults due to multiple testing, a two sided p-value of 0.01 was
considered statistically significant.
Recently published guidelines on the interpretation of
clinical relevant changes of EORTC QLQ-C30 scores were ap-
plied (trivial, small, medium or large differences per scale).17
For scales not included in the guideline, changes were evalu-
ated according to Osoba, who found for the EORTC QLQ-C30
that patients valued a change of 5–10% as ‘little’, 10–20% as
‘moderate’ and more than 20% as ‘very much’ difference.18
3. Results
3.1. Study population and compliance
The PORTEC-2 trial accrued 427 patients between 2002 and
2006; 214 patients were allocated to EBRT and 213 to VBT.
Baseline questionnaires and at least one follow-up question-
naire were received from 348 patients (81%), hereafter re-
ferred to as ‘responders’. At the time of analysis (30th June
2011), 268 of the 348 responders were alive, disease free and
had reached the 5-year follow-up time point, of whom 206
(76%) returned the 5-year questionnaire (Web Appendix A).The median follow-up was 65 months (range 18–106 months),
both for the whole trial population and for the responders.
All returned questionnaires were complete for all items of
the QLQ-C30 in 82% of the responders, and for PR25 items in
92%; when allowing up to two missing items, these rates were
95% and 97%. In contrast, the sexual functioning subscale was
complete for all items in 65%, and the sexual symptom sub-
scale could be calculated for 81% of responders who were sex-
ually active. The treatment groups did not differ with regard
to questionnaire response rates and missing items. Although
there were more EBRT patients among the non-responders (51
EBRT versus 31 VBT patients, p = 0.02), patient characteristics
were equally balanced between the EBRT and VBT group and
between responders and non-responders (Table 1).
3.2. Patient functioning
For both treatment groups, global heath status and function-
ing scales were low at baseline and showed a medium to large
improvement during radiotherapy and in the first 6 months,
reaching a plateau within range of the scores of the norm
population at 6–12 months (Fig. 1 and Table 2). Cognitive func-
tioning remained unchanged from baseline onwards.
Patients treated with vaginal brachytherapy (VBT) reported
significantly better social functioning scores, both at comple-
tion of VBT and during follow-up, than patients treated with
EBRT. The maximum difference in mean social functioning
scores between the groups was small (EBRT 83 versus VBT
89, p-randomisation = 0.005); this difference remained during
the first year of follow-up.
Sexual activity and interest were lowest at baseline (i.e.
after surgery), when 15% of the patients indicated that they
were sexually active. There was a large increase of both inter-
est and activity increased during the first 6 months to reach a
plateau (39% active), without significant differences between
the treatment groups (Fig. 1 and Table 2). For both EBRT and
VBT patients however, mean sexual interest and activity
scores were significantly lower than those of the age-matched
norm-population. The maximum difference between EBRT or
VBT patients and the norm population in mean sexual inter-
est after 12 months was small and ranged between 6 and 10
points, and in sexual activity between 4 and 8 points. Among
the patients who indicated they were active, 81% reported on
their sexual symptoms. There were no significant differences
in sexual symptoms between patients treated with EBRT or
VBT. However, the norm population reported significantly less
vaginal dryness and higher levels of sexual enjoyment.
3.3. Symptom scores
Patients treated with EBRT reported a large increase of diar-
rhoea scores at completion of RT, in contrast to VBT patients
(31 EBRT versus 10 VBT, p-randomisation < 0.001, Table 3 and
Fig. 2). Diarrhoea scores of EBRT patients, although decreas-
ing, remained at significantly higher levels throughout the
5-year follow-up period, whereas diarrhoea scores in the
VBT group remained at baseline level (p-time < 0.001). There
were no significant differences between diarrhoea scores of
VBT patients and those of the norm population, whereas
Table 1 – Patient characteristics of responders and non-responders.
Responders (n = 348) Non-responders (n = 79)
EBRT (n = 166) VBT (n = 182) p-Valuea No. of Patients % p-Valueb
No. of Patients % No. of Patients %
Age, years
Mean 69.5 70.1 0.45 71.3 0.16
Range 52–88 46–86 52–89
<60 years 7 4.2 6 3.3 0.29 3 3.8 0.33
P60 years 159 95.8 176 96.7 75 96.2
FIGO-stage 0.73 0.99
1B 11 6.1 13 7.2 8 9.2
1C 137 82.9 147 80.7 58 75
2A 18 11 22 12.2 9 11.8
Histologic grade 0.83 0.42
Grade 1 77 46.4 89 48.9 36 46.1
Grade 2 78 47 79 43.4 34 43.4
Grade 3 11 6.6 14 7.7 9 10.5
KPS 0.18 0.10
0 118 71.1 119 65.4 61 78.2
1 47 28.3 59 32.4 16 20.5
2 1 0.6 4 2.2 1 1.3
Comorbidity
IBD 2 1.2 2 1.1 0.93 2 2.6 0.34
Diabetes 19 11.4 31 17 0.14 12 15.4 0.82
Hypertension 61 37 63 34.8 0.68 26 33.3 0.68
Cardiovascular 38 23 42 23.1 0.99 18 23.4 0.95
Other 24 14.5 28 15.5 0.79 14 17.9 0.51
EBRT, external beam radiotherapy; VBT, vaginal brachytherapy.
KPS, Karnofski Performance Score; IBD, inflammatory bowel disease.
FIGO, International Federation of Gynaecology and Obstetrics.
a p-Value for comparison EBRT versus VBT.
b p-Value for comparison responders versus non-responders.
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throughout 5 years after treatment.
In addition, EBRT patients reported a little increase of fae-
cal leakage 6 months after radiotherapy (11% EBRT versus 3%
VBT, p-randomisation < 0.001), remaining stable with further
follow-up. Among the bowel symptoms, the item ‘limitations
of daily activities due to bowel problems’ showed the largest
difference between the treatment groups, in favour of VBT
(23% EBRT versus 7% VBT, p-randomisation < 0.001). More-
over, EBRT patients reported a moderately increased need to
remain close to the toilet.
Fatigue scores of both EBRT and VBT patients returned to
levels in range with the norm-population after 6 months,
whilst pain scores of both treatment groups were lower than
those of the norm population.
4. Discussion
The current analysis of long-term HRQL of patients treated in
the PORTEC-2 trial with a median follow-up of 65 months
found a continuing long-term impact of EBRT on HRQL. Espe-
cially diarrhoea and faecal leakage were increased after EBRT,
leading to a higher need to remain close to a toilet; more lim-
itations of daily activities due to bowel problems; and a lower
level of social functioning. HRQL of patients treated with VBT
remained very similar to that of a healthy age-matched norm
population. In contrast, sexual aspects of HRQL aftertreatment for endometrial cancer were lower than those of
the norm population, irrespective of the type of adjuvant
radiotherapy.16
Diarrhoea scores of VBT patients remained at the norm
population level, whilst the scores of EBRT patients remained
significantly increased up to 5 years after treatment. Further-
more, scores on the global health status scale and functioning
scales of both EBRT and VBT patients were significantly lower
than norm data at baseline (after surgery), and recovered in
the first 6 months to reach a plateau within range of the
age-matched norm population. A similar pattern was found
for fatigue scores. These results indicate that for most women
the stressful period of diagnosis and treatment for endome-
trial cancer has a clear but transient influence on their gen-
eral functioning.
The persisting increased rates of bowel symptoms after
EBRT are consistent with the increased gastrointestinal toxic-
ity rates after EBRT found in randomised trials and retrospec-
tive studies on long-term morbidity after pelvic
radiotherapy.19–21 In the HRQL analysis of PORTEC-1 trial sur-
vivors 15 years after treatment, increased bowel symptom
rates were reported by EBRT patients as compared to those
treated with surgery alone, indicating the persistence of these
symptoms over time.9
Reported late side-effects of vaginal brachytherapy include
atrophic changes in the vaginal mucosa leading to vaginal
dryness, painful intercourse and vaginal fibrosis leading to
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Fig. 1 – Patient functioning on subscales from European Organization for Research and Treatment of Cancer C30 questionnaire
(EORTC QLQ-C30) and sexual activity score of the ovarian cancer questionnaire module (EORTC OV-28). A higher score
indicates a higher level of functioning or activity. For EBRT and VBT error bars represent 99% Confidence Interval (CI), for Norm
the error bars represent the 95% CI. The vertical axis is in the (A–C) upper-50% range; and (D) lower-50% range. VBT, vaginal
brachytherapy; EBRT, external-beam radiotherapy; Norm, age-matched Dutch norm population; RT, radiation therapy.
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changes as assessed at gynaecological examinations showed
an increase of grade 1 and 2 mucosal atrophy from 6 months
onwards (at 3 years 17% after EBRT versus 35% after VBT).7
Despite the increased rate of grade 1–2 mucosal atrophy, there
were no significant differences in sexual functioning and sex-
ual symptoms between patients treated with EBRT or VBT.
However, sexual functioning (activity and interest) scores of
both EBRT and VBTwere lower than those of the age-matched
norm-population and sexual symptoms were increased. The
rates of sexual activity and symptom scores reported by POR-
TEC-2 trial patients were similar to the long-term scores of
PORTEC-1 trial survivors, also those treated with surgery
alone, suggesting an impact of cancer diagnosis and treat-
ment on sexual aspects of HRQL.9 Limitations to any conclu-
sion are the low rate of sexual activity in this elderly
population, and the lower completion rate of the sexual func-
tioning questions.
A striking finding of the 15-year HRQL analysis of the POR-
TEC-1 trial was the increase rate of urinary urgency and
incontinence. In the current analysis of 5-year HRQL in the
PORTEC-2 trial, there were no differences in urinarysymptoms between the groups. However, from 12 months
onwards a trend towards higher incontinence and urgency
scores after EBRT seemed to emerge. Possibly, these late uri-
nary symptoms develop as a result of added long-term impact
of EBRT upon normal ageing changes of the pelvic floor mus-
cles. A future analysis of very long-term HRQL in PORTEC-2
will include questions on incontinence pad usage. Future
studies should investigate preventive measures to maintain
pelvic floor functioning to diminish the added effect of RT
on normal ageing.
In conclusion, up to 5 years after treatment, EBRT has a
clinically relevant, bowel symptom-related negative impact
on HRQL, with limitation of daily activities. Global health
status and functioning scores of all patients returned to lev-
els of an age-matched Dutch norm population after 6–12
months, indicating that for most women diagnosis and
treatment for endometrial cancer has a clear but transient
influence on their general functioning. Compared to the
norm population, EC patients reported lower levels of sexual
functioning and more sexual symptoms after treatment,
without differences between patients who received EBRT or
VBT.
Table 2 – Patient functioning scores from EORTC QLQ-C30 and sexual functioning and symptom scores from OV-28.
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Fig. 2 – Single item symptom scores from European Organization for Research and Treatment of Cancer C30 questionnaire
(EORTC QLQ-C30) and prostate cancer questionnaire module (EORTC PR-25). A higher score indicates a higher level of
symptoms. For EBRT and VBT error bars represent 99% Confidence Interval (CI), for Norm the error bars represent the 95% CI.
The vertical axis is in the (A–F) lower-50% range. VBT, vaginal brachytherapy; EBRT, external-beam radiotherapy; Norm, age-
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Appendix A
The following Radiation Oncology institutions participated in
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